The Evolving Role of Oestrogens and Their Receptors in the Development and Progression of Prostate Cancer

European Urology

Volumn 55, Issue 3, 2009, Pages 533-542

  Bonkhoff, Helmut ^a   Berges, Richard ^b  

^a Pathology Laboratories   (Germany)

^b PAN Klinik am Neumarkt   (Germany)

Author keywords

HGPIN; Oestrogen receptor alpha and beta; Oestrogens; Phytoestrogens; Progesterone receptor; Prostate cancer; TMPRSS2 ERG

Indexed keywords

3 INDOLEMETHANOL; BIOLOGICAL MARKER; DUTASTERIDE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FINASTERIDE; FULVESTRANT; GENISTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHYTOESTROGEN; PLACEBO; RALOXIFENE; RESVERATROL; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TOREMIFENE; TRIOXIFENE;

ANGIOGENESIS; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL PROLIFERATION; CELL STRAIN LNCAP; CLINICAL TRIAL; DIETARY INTAKE; DRUG INHIBITION; GENE CONTROL; GENE EXPRESSION; GENE FUSION; GENE SILENCING; HUMAN; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; METASTASIS; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN DEPLETION; PROTEIN EXPRESSION; REVIEW; RNA SPLICING; TUMOR BIOPSY; TUMOR GROWTH; UPREGULATION;

ANIMALS; DISEASE PROGRESSION; ESTROGENS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN;

EID: 58849083630     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.10.035     Document Type: Review

References (49)

1. Chang W.Y., and Prins G.S. Estrogen receptor-beta: implications for the prostate gland. Prostate 40 (1999) 115-124
2. Ho S.-M. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 91 (2004) 491-503
3. Risbridger G.P., Ellem S.J., and McPherson S.J. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signalling. J Mol Endocrinol 39 (2007) 183-188
4. Singh P.B., Matanhelia S.S., and Martin F.L. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer 44 (2008) 928-936
5. Bonkhoff H., Fixemer T., Hunsicker I., and Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 155 (1999) 641-647
6. Leav I., Lau K.M., Adams J.Y., et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159 (2001) 79-92
7. Fixemer T., Remberger K., and Bonkhoff H. Differential expression of the estrogen receptor beta (ER beta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54 (2003) 79-87
8. Bonkhoff H., and Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28 (1996) 98-106
9. Bosland M.C. The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention. Rev Urol 7 Suppl 3 (2005) 4-10
10. Ricke W.A., McPherson S.J., Bianco J.J., Cunha G.R., Wang Y., and Risbridger G.P. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signalling. FASEB J 22 (2008) 1512-1520
11. De Marzo A.M., Platz E.A., Sutcliffe S., et al. Inflammation in prostate carcinogenesis. Nature Reviews Cancer 7 (2007) 256-269
12. Price D., Stein B., Sieber P., et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 176 (2006) 965-970
13. Taneja S.S. Drug therapies for eradicating high-grade prostatic intraepithelial neoplasia in the prevention of prostate cancer. Rev Urol 7 Suppl 3 (2005) 19-29
14. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93 (1996) 5925-5930
15. Klein E.A. Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention. Rev Urol 4 Suppl 5 (2002) 18-28
16. Zhou J.R., Gugger E.T., Tanaka T., Guo Y., Blackburn G.L., and Clinton S.K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129 (1999) 1628-1635
17. Bylund A., Zhang J.X., Bergh A., et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate 42 (2000) 304-314
18. Mentor-Marcel R., Lamartiniere C.A., Eltoum I.E., Greenberg N.M., and Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61 (2001) 6777-6782
19. Shen J.C., Klein R.D., Wei Q., et al. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 29 (2000) 92-102
20. Fritz W.A., Wang J., Eltoum I.E., and Lamartiniere C.A. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol 186 (2002) 89-99
21. Wang J., Eltoum I.E., and Lamartiniere C.A. Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog 6 (2007) 3
22. Stettner M., Kaulfuss S., Burfeind P., et al. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 6 (2007) 2626-2633
23. Matsumura K., Tanaka T., Kawashima H., and Nakatani T. Involvement of the estrogen receptor beta in genistein-induced expression of p21(waf1/cip1) in PC-3 prostate cancer cells. Anticancer Res 28 (2008) 709-714
24. Harper C.E., Patel B.B., Wang J., Arabshahi A., Eltoum I.A., and Lamartiniere C.A. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28 (2007) 1946-1953
25. Hedelin M., Bälter K.A., Chang E.T., et al. Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. Prostate 66 (2006) 1512-1520
26. Bonkhoff H., Fixemer T., Hunsicker I., and Remberger K. Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate 48 (2001) 285-291
27. Saramäki O.R., Harjula A.E., Martikainen P.M., Vessella R.L., Tammela T.L., and Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14 (2008) 3395-3400
28. Setlur S.R., Mertz K.D., Hoshida Y., et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100 (2008) 815-825
29. Mehra R., Tomlines S., Yu J., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68 (2008) 3584-3590
30. Ricke W., Wang Y., and Cunha G. Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation 75 (2007) 871-882
31. Fromont G., Yacoub M., Valeri A., et al. Differential expression of genes related to androgen and estrogen metabolism in hereditary versus sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 17 (2008) 1505-1509
32. Kruithof-Dekker I.G., Têtu B., Janssen P.J., and Van der Kwast T.H. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. J Urol 156 (1996) 1194-1197
33. Henshall S.M., Quinn D.I., Lee C.S., et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 61 (2001) 423-427
34. Li R., Wheeler T., Dai H., Frolov A., Thompson T., and Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 28 (2004) 928-934
35. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39
36. Neubauer B.L., Best K.L., Counts D.F., et al. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. Prostate 27 (1995) 220-229
37. Kim I.Y., Seong D.H., Kim B.C., et al. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Res 62 (2002) 3649-3653
38. Kim I.Y., Kim B.C., Seong D.H., et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 62 (2002) 5365-5369
39. Neubauer B.L., McNulty A.M., Chedid M., et al. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model. Cancer Res 63 (2003) 6056-6062
40. Bhattacharyya R.S., Krishnan A.V., Swami S., and Feldman D. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther 5 (2006) 1539-1549
41. Chadha M.K., Ashraf U., Lawrence D., et al. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. Prostate 68 (2008) 1461-1466
42. Raghow S., Hooshdaran M.Z., Katiyar S., and Steiner M.S. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62 (2002) 1370-1376
43. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179 (2008) 152-155
44. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 26 (2008) 1824-1829
45. Locke J.A., Guns E.S., Lubik A.A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68 (2008) 6407-6415
46. Giton F., de la Taille A., Allory Y., et al. Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa). J Steroid Biochem Mol Biol 109 (2008) 158-167
47. Sasaki M., Tanaka Y., Perinchery G., et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 94 (2002) 384-390
48. Lau K.M., LaSpina M., Long J., and Ho S.M. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 60 (2000) 3175-3182
49. Leung Y.K., Mak P., Hassan S., and Ho S.M. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signalling. Proc Natl Acad Sci USA 103 (2006) 13163-13167